United Therapeutics (NasdaqGS:UTHR) received FDA Regenerative Medicine Advanced Therapy designation for its investigational miroliverELAP external liver assist product. The RMAT designation recognizes ...
BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...
(RTTNews) - Trestle Biotherapeutics, Inc. has partnered with Humacyte, Inc. (HUMA) to explore synergies in bioengineering vascularized organs for transplantation. Trestle Bio, a preclinical-stage ...
A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway;1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah ...
United Therapeutics’ bioengineered external liver assist system developed to treat patients with acute forms of chronic liver failure proved promising based on early phase 1 trial results. Five ...
BROOKLYN, N.Y., April 2, 2025 /PRNewswire/ -- Xylyx Bio, Inc., a regenerative medicine company, announced that it has received $1,000,000 from the Richard M. Bartlett Jr. Memorial Foundation and ...
Intermountain Medical Center participated in a trial of the first bioengineered external liver, designed to help acute liver failure patients or are not eligible for or are waiting for a transplant a ...
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...
In a breakthrough that brings bioengineered organs one step closer to reality, scientists have created lab-grown liver tissue capable of forming its own blood vessels. A team from Cincinnati ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results